Signature Equity Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
Signature Equity Partners's VRTX Position: Q1 2026 in Review
Signature Equity Partners increased its Vertex Pharmaceuticals (VRTX) stake by 689% in Q1 2026, buying an estimated $141K and bringing the position to 347 shares worth $155K. The position accounts for 0.08% of the portfolio, ranked #223.
Signature Equity Partners first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Signature Equity Partners held 347 shares of Vertex Pharmaceuticals worth $155K as of Q1 2026.
- Signature Equity Partners bought 303 Vertex Pharmaceuticals shares in Q1 2026, an estimated $141K.
- Vertex Pharmaceuticals made up 0.08% of Signature Equity Partners's portfolio in Q1 2026, its #223 holding.
- Signature Equity Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.